| 1791 |
LUCISELUME |
SELUMETINIB 25 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 WHO HAVE SYMTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
03 L 1073/24 |
14-MAR-2023 |
13-MAR-2027 |
View |
| 1792 |
LUCISETA |
SPARSENTAN 400 MG |
TABLET |
BOTTLE |
TO REDUCE PROTEINURIA IN ADULT WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY AT RISK OF RAPID DISEASE PROGRESSION, GENERALLY A URINE PROTEIN TO CREATININE RATION >=1.5 G/G |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
10 L 1036/23 |
30-OCT-2023 |
29-OCT-2026 |
View |
| 1793 |
LUCISETA |
SPARSENTAN 200 MG |
TABLET |
BOTTLE |
TO REDUCE PROTEINURIA IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY AT RISK OF RAPID DISEASE PROGRESSION, GENERALLY A URINE PROTEIN TO CREATININE RATIO >= 1.5 G/G |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
02 L 1302/25 |
25-FEB-2025 |
24-FEB-2030 |
View |
| 1794 |
LUCISORA |
SORAFENIB 200 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
09 L 1224/24 |
31-OCT-2024 |
30-OCT-2029 |
View |
| 1795 |
LUCISOT |
SOTORASIB 120 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
04 L 0960/23 |
19-APR-2023 |
18-APR-2026 |
View |
| 1796 |
LUCISOVE |
SOFOSBUVIR 400 MG, VELPATASVIR 100 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1,2,3,4,5 OR 6 INFECTION |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
09 L 1226/24 |
31-OCT-2024 |
30-OCT-2029 |
View |
| 1797 |
LUCISTIR |
STIRIPENTOL 250 MG |
CAPSULE |
BOTTLE |
TREATMENT OF EPILEPTIC ASSOCIATED WITH DRAVET DISEASE |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
12 L 1053/23 |
03-JAN-2024 |
02-JAN-2027 |
View |
| 1798 |
LUCISUNI |
SUNITINIB 12.5 MG |
CAPSULE |
BOTTLE |
TREATMENT OF GASTROINTESTINAL STROMA TUMOR AFTER DISEASE PROGRESSION ON OR INTOLERANCE TO IMATINIB MESYLATE, ADVANCED RENAL CELL CARCINOMA |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
08 L 1166/24 |
21-AUG-2024 |
20-AUG-2027 |
View |
| 1799 |
LUCISUNI |
SUNITINIB 25 MG |
CAPSULE |
BOTTLE |
TREATMENT OF GASTROINTESTINAL STROMA TUMOR AFTER DISEASE PROGRESSION ON OR INTOLERANCE TO IMATINIB MESYLATE, ADVANCED RENAL CELL CARCINOMA |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
08 L 1165/24 |
21-AUG-2024 |
20-AUG-2027 |
View |
| 1800 |
LUCISUNI |
SUNITINIB 50 MG |
CAPSULE |
BOTTLE |
TREATMENT OF GASTROINTESTINAL STROMA TUMOR AFTER DISEASE PROGRESSION ON OR INTOLERANCE TO IMATINIB MESYLATE, ADVANCED RENAL CELL CARCINOMA |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
08 L 1164/24 |
21-AUG-2024 |
20-AUG-2027 |
View |
